全文获取类型
收费全文 | 5277篇 |
免费 | 272篇 |
国内免费 | 16篇 |
专业分类
耳鼻咽喉 | 24篇 |
儿科学 | 254篇 |
妇产科学 | 66篇 |
基础医学 | 644篇 |
口腔科学 | 124篇 |
临床医学 | 369篇 |
内科学 | 1110篇 |
皮肤病学 | 119篇 |
神经病学 | 326篇 |
特种医学 | 132篇 |
外科学 | 740篇 |
综合类 | 112篇 |
一般理论 | 6篇 |
预防医学 | 284篇 |
眼科学 | 312篇 |
药学 | 565篇 |
中国医学 | 38篇 |
肿瘤学 | 340篇 |
出版年
2023年 | 50篇 |
2022年 | 47篇 |
2021年 | 210篇 |
2020年 | 124篇 |
2019年 | 142篇 |
2018年 | 197篇 |
2017年 | 145篇 |
2016年 | 161篇 |
2015年 | 205篇 |
2014年 | 241篇 |
2013年 | 281篇 |
2012年 | 421篇 |
2011年 | 446篇 |
2010年 | 218篇 |
2009年 | 185篇 |
2008年 | 273篇 |
2007年 | 300篇 |
2006年 | 265篇 |
2005年 | 222篇 |
2004年 | 189篇 |
2003年 | 179篇 |
2002年 | 184篇 |
2001年 | 122篇 |
2000年 | 105篇 |
1999年 | 74篇 |
1998年 | 24篇 |
1997年 | 23篇 |
1996年 | 39篇 |
1995年 | 16篇 |
1994年 | 8篇 |
1993年 | 13篇 |
1992年 | 31篇 |
1991年 | 34篇 |
1990年 | 40篇 |
1989年 | 45篇 |
1988年 | 41篇 |
1987年 | 36篇 |
1986年 | 29篇 |
1985年 | 30篇 |
1984年 | 25篇 |
1983年 | 22篇 |
1982年 | 14篇 |
1981年 | 10篇 |
1980年 | 9篇 |
1979年 | 23篇 |
1977年 | 13篇 |
1974年 | 9篇 |
1973年 | 7篇 |
1971年 | 7篇 |
1970年 | 9篇 |
排序方式: 共有5565条查询结果,搜索用时 250 毫秒
1.
Inflammopharmacology - Colony Stimulating Factor-1 (CSF-1)/Colony Stimulating Factor-1 Receptor (CSF-1R) signaling axis plays an essential role in the development, maintenance, and proliferation of... 相似文献
2.
Dongbing Lai Emma C. Johnson Sarah Colbert Gayathri Pandey Grace Chan Lance Bauer Meredith W. Francis Victor Hesselbrock Chella Kamarajan John Kramer Weipeng Kuang Sally Kuo Samuel Kuperman Yunlong Liu Vivia McCutcheon Zhiping Pang Martin H. Plawecki Marc Schuckit Jay Tischfield Leah Wetherill Yong Zang Howard J. Edenberg Bernice Porjesz Arpana Agrawal Tatiana Foroud 《Alcoholism, clinical and experimental research》2022,46(3):374-383
3.
Syed Khizer Hasan Nikhil V. Patkar Deepan Rajamanickam Anant Gokarn Antonio R. Lucena-Araujo Prashant Tembhare Bhausaheb Bagal Pratibha Kadam Amare Hasmukh Jain Sumeet Gujral Manju Sengar Papagudi Ganesan Subramanian Navin Khattry 《Hematological oncology》2020,38(5):808-816
The high expression of brain and acute leukemia, cytoplasmic (BAALC) and ETS-related gene (ERG) has been reported to influence the outcome in acute myeloid leukemia (AML), but due to limited prospective studies, their role as prognostic factors is unclear. At diagnosis, the prognostic value of BAALC and ERG expression with respect to other cytogenetic and molecular markers was analyzed in 149 AML patients. Patients were divided into quartiles which resulted in the formation of four groups (G1–G4) based on expression values of BAALC and ERG and clinical response defined across groups. Groups with similar survival probabilities were merged together and categorized subsequently as high versus low expressers. Patients with high BAALC and ERG expression had significantly lower overall survival (OS; BAALC: p = 0.001 at 5 years 29.4% vs. 69.8%; ERG: p < 0.0001 at 5 years 4% vs. 50.4%) and disease-free survival (BAALC: p = 0.001 at 5 years 19.5% vs. 69.8%; ERG: p < 0.0001 at 5 years 4.2% vs. 47%). Patients were further stratified combining BAALC and ERG expression in an integrative prognostic risk score (IPRS). After a median follow-up of 54 months (95% CI 45–63 months) among survivors, IPRS for high versus low expressers was a significant predictor for OS (BAALC + ERG: 4% vs. 71.6%, p < 0.0001) and DFS (BAALC + ERG: 4.5% vs. 74.1%, p < 0.0001). In a multivariate model, IPRS of BAALC + ERG expression retained prognostic significance for OS (hazard ratio [HR] 2.96, 95%CI 1.91–4.59, p < 0.001) and DFS (HR 3.61, 95%CI 2.26–5.76, p < 0.001). 相似文献
4.
Pregnant women are among the high-risk population for severe coronavirus disease 2019 (COVID-19) with unfavorable peripartum outcomes and increased incidence of preterm births. Hemolysis, the elevation of liver enzymes, and low platelet count (HELLP) syndrome and severe preeclampsia are among the leading causes of maternal mortality. Evidence supports a higher odd of pre-eclampsia in women with COVID-19, given overlapping pathophysiology. Involvement of angiotensin-converting enzyme 2 receptors by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for the entry to the host cells and its downregulation cause dysregulation of the renin-angiotensin-aldosterone system. The overexpression of Angiotensin II mediated via p38 Mitogen-Activated Protein Kinase pathways can cause vasoconstriction and uninhibited platelet aggregation, which may be another common link between COVID-19 and HELLP syndrome. On PubMed search from January 1, 2020, to July 30, 2022, we found 18 studies on of SARS-COV-2 infection with HELLP Syndrome. Most of these studies are case reports or series, did not perform histopathology analysis of the placenta, or measured biomarkers linked to pre-eclampsia/HELLP syndrome. Hence, the relationship between SARS-CoV-2 infection and HELLP syndrome is inconclusive in these studies. We intend to perform a mini-review of the published literature on HELLP syndrome and COVID-19 to test the hypothesis on association vs causation, and gaps in the current evidence and propose an area of future research. 相似文献
5.
6.
Sameer Arora Kamal Shemisa Muthiah Vaduganathan Arman Qamar Ankur Gupta Sushil K. Garg Dharam J. Kumbhani Helen Mayo Houman Khalili Ambarish Pandey Sandeep R. Das 《Journal of the American College of Cardiology》2019,73(19):2454-2464
Ticagrelor is a cornerstone of modern antithrombotic therapy alongside aspirin in patients with acute coronary syndrome and after percutaneous coronary intervention. Adverse effects such as bleeding and dyspnea have been associated with premature ticagrelor discontinuation, which may limit any potential advantage of ticagrelor over clopidogrel. The randomized trials of ticagrelor captured adverse events, offering the opportunity to more precisely quantify these effects across studies. Therefore, a meta-analysis of 4 randomized clinical trials of ticagrelor conducted between January 2007 and June 2017 was performed to quantify the incidence and causes of premature ticagrelor discontinuation. Among 66,870 patients followed for a median 18 months, premature ticagrelor discontinuation was seen in 25%; bleeding was the most common cause of discontinuation followed by dyspnea. Versus the comparators, the relative risk of dyspnea-related discontinuation during follow-up was 6.4-fold higher, the relative risk of bleeding was 3.2-fold higher, and the relative risk of discontinuation due to any adverse event was 59% higher for patients receiving ticagrelor. Understanding these potential barriers to adherence to ticagrelor is crucial for informed patient-physician decision making and can inform future efforts to improve ticagrelor adherence. This review discusses the incidence, causes, and biological mechanisms of ticagrelor-related adverse effects and offers strategies to improve adherence to ticagrelor. 相似文献
7.
Rimesh Pal Naresh Sachdeva Soham Mukherjee Vikas Suri Deepy Zohmangaihi Sant Ram Goverdhan Dutt Puri Ashish Bhalla Shiv Lal Soni Navin Pandey Anil Bhansali Sanjay Kumar Bhadada 《Diabetes & Metabolic Syndrome: Clinical Research & Reviews》2021,15(1):193-196
Background and aimsPatients with diabetes mellitus (DM) often demonstrate impaired antibody response to influenza/hepatitis B vaccines. Hence, we compared anti-SARS-CoV-2 antibody response in non-severe COVID-19 patients with and without type 2 diabetes mellitus (T2DM).MethodsRecords of non-severe COVID-19 patients admitted at our institution between April 10, 2020 and May 20, 2020 were retrieved. Qualitative detection of total (IgG + IgM) anti-SARS-CoV-2 antibody was performed using electrochemiluminescence immunoassay in plasma samples collected at least 14 days post-polymerase chain reaction (PCR) confirmation of diagnosis.ResultsThirty-one non-severe COVID-19 patients were included. Nine patients (29%) had T2DM with mean HbA1c at admission of 8.3 ± 1.0%. Anti-SARS-CoV-2 antibody was estimated at a median of 16 (14–17) days post-PCR confirmation of COVID-19 diagnosis. Only three patients (10%) were seronegative, and all had T2DM. Patients with T2DM were more likely to have non-detectable anti-SARS-CoV-2 antibodies than those without DM (p = 0.019).ConclusionsCOVID-19 patients with T2DM may not undergo seroconversion even after two weeks of diagnosis. Impaired seroconversion could theoretically increase the risk of reinfections in patients with DM. However, the finding requires validation in large-scale studies involving serial estimations of anti-SARS-CoV-2 antibodies in patients with and without DM. 相似文献
8.
9.
10.
Arunaloke Chakrabarti Prashant Sood Shivaprakash M. Rudramurthy Sharon Chen Joseph Jillwin Ranganathan Iyer Ajanta Sharma Belgode Narasimha Harish Indranil Roy Anupma J. Kindo Deepinder Chhina Jayanthi Savio Deepak Mendiratta Malini R. Capoor Shukla Das Anita Arora Jagdish Chander Immaculata Xess Appalaraju Boppe Ujjwayini Ray Ratna Rao Vandana Kalwaje Eshwara Sangeeta Joshi Atul Patel Raman Sardana Anjali Shetty Umabala Pamidimukkala for the SIHAM Candidemia Network 《Mycoses》2020,63(11):1149-1163